Clinical Trials in Chicago

Showing 6001-6020 of 20,493 trials

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

NCT04101357

This first-in-human (FIH) trial aimed to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide. BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune checkpoint inhibitors.

Solid TumorExtensive-stage Small Cell Lung Cancer

BioNTech SE54 participantsStarted Jun 2020

Los Angeles, California, United States • Chicago, Illinois, United States • Greenville, South Carolina, United States +9 more locations

COMPLETEDPhase 22.2 miles

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

NCT03235544

This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.

Lymphoma

Incyte Corporation162 participantsStarted Nov 2017

Birmingham, Alabama, United States • Santa Rosa, California, United States • Aurora, Colorado, United States +100 more locations

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Find Trials by Condition in Chicago

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function

Angio-IMR and Cardiac MR-derived MVO in STEMI Patients

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

HPV Vaccine Intervention for Young Sexual Minority Men

IMPROVE AKI Cluster-Randomized Trial

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

A Study of LY3561774 in Participants With Mixed Dyslipidemia

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay